Explore
Validate
Learn
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Immunohistochemistry [1]
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF-296-NA - Provider product page
- Provider
- R&D Systems
- Product name
- Human NRG1-alpha/HRG1-alpha EGF Domain Antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified. Detects human NRG1-alpha/HRG1-alpha in direct ELISAs and Western blots.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Antigen sequence
Q7RTV8- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Type I neuregulin1α is a novel local mediator to suppress hepatic gluconeogenesis in mice.
Glial growth factor 2 promotes functional recovery with treatment initiated up to 7 days after permanent focal ischemic stroke.
HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors.
Arai T, Ono Y, Arimura Y, Sayama K, Suzuki T, Shinjo S, Kanai M, Abe SI, Semba K, Goda N
Scientific reports 2017 Feb 20;7:42959
Scientific reports 2017 Feb 20;7:42959
Glial growth factor 2 promotes functional recovery with treatment initiated up to 7 days after permanent focal ischemic stroke.
Iaci JF, Ganguly A, Finklestein SP, Parry TJ, Ren J, Saha S, Sietsma DK, Srinivas M, Vecchione AM, Caggiano AO
Neuropharmacology 2010 Dec;59(7-8):640-9
Neuropharmacology 2010 Dec;59(7-8):640-9
HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors.
Sun M, Behrens C, Feng L, Ozburn N, Tang X, Yin G, Komaki R, Varella-Garcia M, Hong WK, Aldape KD, Wistuba II
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Aug 1;15(15):4829-37
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Aug 1;15(15):4829-37
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- NRG1-alpha/HRG1-alpha in Human Breast. NRG1-alpha/HRG1-alpha was detected in paraffin-embedded sections of human breast using Goat Anti-Human NRG1-alpha/HRG1-alpha EGF Domain Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-296-NA) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-AEC Cell & Tissue Staining Kit (red; Catalog # CTS009) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Cell Proliferation Induced by NRG1-alpha/HRG1-alpha and Neutralization by Human NRG1-alpha/HRG1-alpha Antibody. Recombinant Human NRG1-alpha/HRG1-alpha EGF Domain (Catalog # 296-HR) stimulates proliferation in the MCF-7 human breast cancer cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human NRG1-alpha/HRG1-alpha EGF Domain (125 ng/mL) is neutralized (green line) by increasing concentrations of Human NRG1-alpha/HRG1-alpha EGF Domain Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-296-NA). The ND50 is typically 7-30 µg/mL.
